Cancer Biopsy Market Size, Share & Trends Analysis Report By Product (Kits & Consumables, Instruments, Services), By Type (Tissue Biopsies, Liquid Biopsies), By Application, And Segment Forecasts, 2021 - 2027

Report Overview

The global cancer biopsy market size was valued at USD 21.26 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 11.13% from 2021 to 2027. The increasing prevalence of oncology indications, coupled with the growing geriatric population, is a major factor expected to fuel market growth. In addition, the advent of liquid biopsy and the ongoing developments in biopsy techniques are expected to propel the growth of the market. Various techniques including endoscopic, bone marrow, skin, needle, and surgical biopsies are incorporated in the oncology diagnostics field. Amongst these techniques, needle biopsies are considered a preferred technique aimed at the early detection of patients. However, advantages of fine-needle aspiration (FNA) type needle biopsies such as less invasion along with lesser time for the outcomes have supplemented the market growth.

Additionally, series of advancements in image-guided biopsies and expanding applications of the same has been marked as key trends in recent years. For instance, in 2017, magnetic resonance imaging targeted biopsies were evaluated for their potential in prostate tumor detection. The study concluded that multi-parametric magnetic resonance (MR) imaging-based biopsies helped in minimizing false-negative results, further enhancing risk assessment.

This test confirms tumor presence via the identification of genetic markers in the blood. This technique is gaining immense popularity since its inception and this is attributed to the benefits associated with it such as cost-effectiveness, lesser complexity and time consumption, and minimal pain during the biopsy. Additionally, various companies operating in data analysis and diagnostics are entering this market.

The emergence of liquid biopsy for cancer diagnosis, screening, prognosis, and treatment monitoring has significantly enhanced the competition and capabilities in this market. Operating entities are undertaking strategic initiatives to enter this arena and are engaged in conducting liquid biopsies, which is expected to fuel the growth of the market within clinical settings. Currently, liquid biopsy is used in patients who cannot undergo a tissue biopsy for advanced, metastatic cancer diagnosis.

Type Insights

Tissue biopsy accounted for the largest revenue share of over 80.0% in 2020. It is still considered to be a mainstay of biopsies and is largely adopted across various cancer diagnosis applications. This is attributed to robust research activities evaluating its safety and efficacy, which has contributed to this segment growth.

Advancements targeted towards enhancing tissue biopsy procedures are expected to maintain the lead of the tissue biopsy segment for the next few years. For instance, Cernostics is developing an assay suitable for diagnosing cancer patients suffering from Barrett's Esophagus. This one-of-a-kind diagnostic test makes use of biopsy images that are digitally scanned, which aids in the analysis and quantification of alterations occurring at the cellular or molecular levels within a tissue.

The rising preference for liquid biopsy among physicians has been observed in recent years, which is supplemented by its ability to offer disease snapshots from the primary and distant tumor sites. This approach is put to use in personalized medicine treatment, wherein tumor markers are sampled repeatedly to alter the therapy based on the patient’s response to the treatment.

Application Insights

Breast biopsy held the largest share of over 14.0% in 2020. Breast cancer has the largest prevalence rate. Around 1 in 8 U.S. women develop invasive breast cancer as per the U.S. breast cancer statistics. An estimated 276,480 new cases of invasive breast cancer were diagnosed in women in 2020in the U.S., along with more than 40,000 new cases of non-invasive breast cancer.

The rising number of patients suspected of having breast cancer is subjected to microscopic analysis of breast tissue, which is mandatory to obtain a definitive diagnosis, along with detecting the stage and characterization of type. This has propelled the demand for a needle biopsy or surgical biopsy to obtain tissue for microscopic analysis, in turn contributing to the segment growth.

Circulating tumor cells (CTC)-based liquid biopsies have the ability to track the minimal residual disease (MRD) in non-metastatic prostate cancer patients, along with the follow-up evaluations performed to offer independent prognostic insights. A novel European project, Transcan-PROLIPSY is designed to assess the potential of combined use of CTCs, exosomes, and ctDNA as a noninvasive liquid biopsy modality to diagnose prostate cancer followed by its routine evaluation.

Product Insights

Kits and consumables accounted for the largest revenue share of over 60.0% in 2020 as these are integral across various stages of biopsies. Moreover, robust investments by key players operating in this industry have made significant contributions to the segment growth. The segment growth can also be attributed to a considerable increase in the number of patients across the globe that demand instruments and kits to be efficient, accurate, and rapid.

Cancer biopsy has witnessed several developments in terms of instruments, kits, and consumables. With liquid biopsy emerging as a multimodal tool of diagnosis in the field of clinical oncology, the development of efficient products associated with biopsies is pivotal. Though the existing instruments are used predominantly, they are accompanied by various shortcomings. However, the advent of novel technologies is expected to increase the demand for instruments significantly in the coming years.

Several emerging manufacturers are focusing on launching instruments that are able to enhance endoscopy-based biopsies. For instance, BiBBInstruments AB, a Swedish company, has established a strong presence in the instruments market space under the brand – EndoDrill.

Regional Insights

North America accounted for the largest share of over 40.0%in 2020. The region is anticipated to maintain its lead throughout the forecast period, with the U.S. making significant contributions to the regional revenue. In addition, distributors and manufacturers operating in this region aim to distribute and develop novel kits that are well-suited for rapid diagnostic applications.

Moreover, the increasing adoption of liquid biopsies across the U.S. is largely favored by the profitable strategies laid out by the respective government authorities. Regulatory strategies for liquid biopsy-based oncology diagnostics rely on the framework, which has been developed in recent years by the U.S. Food and Drug Administration (FDA). This framework consists of the guidelines associated with enrichment biomarkers and companion diagnostics, and approval precedents. The ultimate success of liquid biopsy regulatory pathways has been supplemented by the incremental value of FDA approval for Clinical Laboratory Improvement Amendment (CLIA)‐developed tests.

Key Companies & Market Share Insights

Key players are contributing to market growth by expanding their diagnostics portfolio, further enhancing the uptake of their proprietary biopsy products. For instance, in March 2021, Illumina, Inc. announced medical device registration for its NextSeq 550Dx platform and associated reagent kits in Russia. Its MiSeq Dx was already approved as a medical device prior to this registration.

Liquid biopsy samples (blood specimens) have to be used with this kit to quantify certain mutations associated with circulating tumor DNA (ctDNA). This product was co-developed by Qiagen and Novartis in the U.S. and with this CE approval, the product is expected to capture the European market. Some prominent players in the global cancer biopsy market include:

• Qiagen N.V.

•  Illumina, Inc.

•  ANGLE Plc

•  BD (Becton, Dickinson and Company)

•  Myriad Genetics

•  Hologic, Inc.

•  Biocept, Inc.

•  Thermo Fisher Scientific, Inc.

•  Danaher

•  F. Hoffmann-La Roche Ltd.

•  Lucence Diagnostics Pte. Ltd.

•  GRAIL, Inc.

•  Guardant Health

•  Exact Sciences Corporation

•  Freenome Holdings, Inc.

•  Biodesix (Integrated Diagnostics)

•  Oncimmune

•  Epigenomics AG

•  HelioHealth (Laboratory for Advanced Medicine)

•  Genesystems, Inc. (Genesys Biolabs)

•  Chronix Biomedical, Inc.

•  Personal Genome Diagnostics Inc.

•  Natera, Inc.

• Personalis Inc.

Cancer Biopsy Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2027. For the purpose of this study, Grand View Research has segmented the global cancer biopsy market report on the basis of product, type, application, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2027)

  • Instruments

  • Kits and Consumables

  • Services

• Type Outlook (Revenue, USD Million, 2018 - 2027)

  • Tissue Biopsies

    • Needle Biopsies

      • Fine Needle Aspiration (FNA)

      • Core Needle Biopsy (CNB)

    • Surgical Biopsies

  • Liquid Biopsies

  • Others

• Application Outlook (Revenue, USD Million, 2018 - 2027)

  • Breast Cancer

  • Colorectal Cancer

  • Cervical Cancers

  • Lung Cancers

  • Prostate Cancers

  • Skin Cancers

  • Blood Cancers

  • Kidney Cancers

  • Liver Cancers

  • Pancreatic Cancers

  • Ovarian Cancers

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2027)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Spain

    • Italy

  • Asia Pacific

    • Japan

    • China

    • India

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia